ALK and cancer: An ongoing study is screening for autologous or allogeneic T cell receptor-transgenic T cells to test against ALK+/- patient-derived and cancer cell lines using in vitro and in vivo models to assess the potential utility of cytotoxic TCR-directed immunotherapies (111).